Christy Santhosh

1 week ago | dagenspharma.dk | Christy Santhosh |Leroy Leo

Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration May 5 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Monday it will invest $40 billion in the U.S. over the next five years, as it seeks to expand its research and manufacturing presence in the country amid U.S. President Donald Trump's tariff threats.

1 week ago | today.westlaw.com | Leroy Leo |Christy Santhosh

(Reuters) -Bristol Myers Squibb said on Monday it will invest $40 billion in the U.S. over the next five years, as it seeks to expand its research and manufacturing presence in the country amid U.S. President Donald Trump's tariff threats.

2 weeks ago | today.westlaw.com | Mariam Sunny |Alan Barona |Leroy Leo |Christy Santhosh

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening disorder, which is expected to bring in blockbuster revenues and drive growth. J&J had acquired the drug, to be sold...

2 weeks ago | marketscreener.com | Christy Santhosh |Puyaan Singh

(Reuters) -AbbVie raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take from sector-specific import duties that could be imposed by the Trump administration. Drugmaker shares, including AbbVie's, have fallen over the past month due to investor concerns around a probe into pharmaceutical imports that sets the stage for U.S. levies on the sector.

2 weeks ago | yahoo.com | Christy Santhosh |Puyaan Singh

By Christy Santhosh and Puyaan Singh(Reuters) -AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped the company beat Wall Street estimates for first-quarter earnings, sending shares up more than 4% in premarket trading. The company said its updated forecast did not reflect any trade policy shifts, including possible U.S. tariffs on the pharmaceutical sector.